Overview
NICE is unable to make a recommendation on inebilizumab (Uplizna) for immunoglobulin G4-related disease. This is because the company did not provide an evidence submission.
Last reviewed: 06 May 2026
Next review: We will review this decision if the company decides to make a submission.